Search / Trial NCT06221670

Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)

Launched by TIANJIN MEDICAL UNIVERSITY CANCER INSTITUTE AND HOSPITAL · Jan 14, 2024

Apply for Trial

Trial Information

Current as of December 22, 2024

Not yet recruiting

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • The subjects will voluntarily sign the informed consent in person, and provide the informed consent before any specific study procedures;
  • • Male and female, ≥18 years old;
  • • Primary non-squamous NSCLC confirmed histologically by the central laboratory;
  • • The subject was clinically confirmed as stage IA2-IB by imaging with tumor lesion size \> 2 cm;
  • • As confirmed by the central laboratory, the tumor contains no common EGFR mutations and ALK fusion variants;
  • • The primary NSCLC must be completely resected by surgery, and all lesions must be removed at the end of the surgery.All surgical margins must be negative. Lobectomy can be done with open surgery or thoracoscopic (VATS);
  • • Central laboratory pathology confirmed solid and/or micropapillary component ≥10%, and/or STAS, and/or pleural invasion, and/or poorly differentiated, and/or complex glands ≥ 10%; PD-L1 TPS ≥ 1% in tumor tissue;
  • • WHO physical status score is 0\~1;
  • • Paraffin-embedded sections (10-15 sheets), or wax blocks or fresh frozen tissue for surgical resection of the lesion should be provided;
  • • Adequate bone marrow reserve or organ function (demonstrated by any of the following laboratory values: absolute neutrophil count ≥1.5×10⁹/L; Platelet count ≥100×10⁹/L; Hemoglobin ≥90 g/L; Alanine aminotransferase ≤ 2.5 ULN; Aspartate aminotransferase ≤2.5 times ULN; Total bilirubin ≤ 1.5 ULN; Serum creatinine ≤1.5 ULN with creatinine clearance ≥60 mL/min \[as measured or calculated by Cockcroft and Gault formulas\]);
  • • At least 2 weeks prior to initiation of the study drug, female subjects should be using highly effective contraceptive methods, pregnancy tests must be negative, and there must be no ongoing breastfeeding prior to initiation of the drug
  • • Subjects voluntarily join this study, with good compliance and cooperation in safety and survival follow-up.
  • Exclusion Criteria:
  • • Exposure to other antitumor therapies before enrollment;
  • • Patients who only received segmental resection and wedge resection;
  • • Patients with any history of active autoimmune disease or autoimmune disease;
  • • Complicated diseases that require the use of immunosuppressive drugs; concurrent diseases that require the use of immunosuppressive agents for systemic or locally absorbable corticosteroids;
  • • Combined with severe heart disease, or combined with New York Heart Association (NYHA) grade 3 or 4 cardiac insufficiency;
  • • Any evidence of prior history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or active interstitial lung disease;
  • • Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, any condition that the investigator considers to be detrimental to patient participation in the study or to adherence to the protocol, or active infections including hepatitis B, hepatitis C, and human immunodeficiency virus (HIV);
  • • Have received preventive or attenuated vaccines within 4 weeks before the first administration;
  • • Patients are unsuitable for participation in this research after comprehensive assessment by the researchers.

Trial Officials

Dongsheng Yue

Principal Investigator

Tianjin Medical University Cancer Institute and Hospital

About Tianjin Medical University Cancer Institute And Hospital

Tianjin Medical University Cancer Institute and Hospital is a leading research and treatment facility dedicated to advancing cancer care and clinical research. Affiliated with Tianjin Medical University, the institute is at the forefront of oncology, combining innovative research methodologies with comprehensive patient care. It emphasizes multidisciplinary approaches to cancer treatment and actively participates in clinical trials aimed at improving therapeutic outcomes. With a commitment to education and collaboration, the institute plays a vital role in enhancing cancer research and treatment protocols both nationally and internationally.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0